Should Investors Buy IRTC as Growth Improves but Risks Stay Elevated?
iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.
IRTC - iRhythm Technologies, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$174.88
DETAILS
HIGH:
$196.00
LOW:
$160.00
MEDIAN:
$168.00
CONSENSUS:
$174.88
UPSIDE:
43.06%
Stock News
iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference
SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference.
iRhythm: The Algorithmic Margin Inflection Changes The Story
iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial inflection: 20.1% revenue growth, 72.8% gross margin, and adjusted EBITDA margin expansion to 19.3%, with raised full-year guidance and record free cash flow. The ZEUS platform's FDA clearance enables significant margin leverage, reducing clinician review time by 50% and targeting $100 million in cost savings over five years.
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Aug.
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform
IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.
Here's Why iRhythm Holdings, Inc. (IRTC) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
iRhythm Technologies $IRTC Shares Sold by Bank of America Corp DE
Bank of America Corp DE trimmed its holdings in iRhythm Technologies (NASDAQ: IRTC) by 41.7% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 432,539 shares of the company's stock after selling 309,231 shares during the period. Bank of America Corp DE owned approximately 1.32% of
iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised
IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm PR Newswire NEW YORK, Aug. 8, 202
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
NEW YORK, Aug. 8, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at iRhythm caused the company to misrepresent or fail to disclose that the Zio AT monitor was a real-time monitor intended for high-risk patients.
iRhythm Combines Strong Performance with VitalConnect Buy to Expand Remote Cardiac Care
Digital healthcare company iRhythm Holdings, Inc. (NASDAQ:IRTC) on Thursday agreed to acquire Vital Connect, Inc., a privately held developer of wearable biosensor technology.
iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript
iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript
iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates
iRhythm Holdings, Inc. (IRTC) came out with quarterly earnings of $0.58 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to a loss of $0.32 per share a year ago.
iRhythm Technologies Q2 Earnings Call Highlights
iRhythm Technologies NASDAQ: IRTC reported second-quarter revenue growth of 20.1% and raised its full-year outlook, while announcing an agreement to acquire VitalConnect to broaden its cardiac monitoring portfolio and enter additional patient-monitoring markets.
iRhythm Holdings Announces Second Quarter 2026 Financial Results
SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Highlights Revenue of $224.2 million, a 20.1% increase compared to second quarter 2025 Gross margin of 72.8%, a 160-basis point increase compared to second quarter 2025 Net loss of $0.4 million, a $13.8 million improvement compared to second quarter 2025 Adjusted EBITDA and adjusted EBITDA margin of $43.3 million and 19.3%, respectively, a $27.6 million and 1,090-basis point improvement, respectively, compared to second quarter 2025 Unrestricted cash, cash equivalents, and marketable securities of $591.3 million as of June 30, 2026 Increased fiscal year 2026 revenue guidance to $880 million to $890 million and adjusted EBITDA margin guidance to 13.0% to 14.0% Recent Operational Highlights Delivered another strong quarter, demonstrated by robust volume led revenue growth and expanded margins, with continued momentum across cardiology, primary care, innovative channels, and international markets Entered into a definitive agreement to acquire Vital Connect, Inc. ("VitalConnect"), a privately held company that offers complementary ambulatory cardiac monitoring technology, for total consideration of approximately $287.5 million.
Bernstein Litowitz Berger & Grossmann LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of iRhythm Technologies, Inc. Common Stock
SAN FRANCISCO, Aug. 6, 2026 /PRNewswire/ -- Bernstein Litowitz Berger & Grossmann LLP announces that the United States District Court for the Northern District of California has approved the following announcement of a proposed class action settlement that would benefit purchasers of common stock of iRhythm Technologies, Inc. (NASDAQ: IRTC): UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA GLAZING EMPLOYERS AND GLAZIERS' UNION LOCAL #27 PENSION AND RETIREMENT FUND, on behalf of itself and all others similarly situated, Plaintiff, v. iRHYTHM TECHNOLOGIES, INC.
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, July
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders.
Price Targets
iRhythm price target lowered to $168 from $180 at Wells Fargo
$168.00
(was $116.92)
Wells Fargo
iRhythm price target raised to $168 from $160 at Truist
$168.00
(was $124.12)
Truist Financial
iRhythm price target raised to $165 from $150 at Evercore ISI
$165.00
(was $130.81)
Vijay Kumar
·
Evercore ISI
iRhythm price target raised to $165 from $160 at Baird
$165.00
(was $128.12)
Robert W. Baird
iRhythm price target raised to $196 from $157 at Canaccord
$196.00
(was $128.12)
Canaccord Genuity
iRhythm Technologies (IRTC) PT Lowered to $192 at Needham
$192.00
(was $128.12)
David Saxon
·
Needham
iRhythm initiated with an Overweight at Stephens
$160.00
(was $106.07)
Stephens
iRhythm price target lowered to $160 from $174 at Truist
$160.00
(was $116.64)
Richard Newitter
·
Truist Financial
iRhythm price target lowered to $150 from $160 at Evercore ISI
$150.00
(was $124.39)
Vijay Kumar
·
Evercore ISI
iRhythm Technologies (IRTC) PT Lowered to $152 at Canaccord
$152.00
(was $113.90)
William Plovanic
·
Canaccord Genuity
iRhythm price target raised to $174 from $170 at Truist
$174.00
(was $120.26)
Truist Financial
iRhythm price target raised to $175 from $166 at Baird
$175.00
(was $122.92)
Robert W. Baird
iRhythm price target lowered to $160 from $170 at Evercore ISI
$160.00
(was $123.41)
Evercore ISI
iRhythm price target lowered to $185 from $225 at Oppenheimer
$185.00
(was $129.16)
Oppenheimer
iRhythm price target raised to $255 from $254 at Needham
$255.00
(was $129.16)
Needham
iRhythm price target lowered to $180 from $198 at Canaccord
$180.00
(was $129.16)
Canaccord Genuity
iRhythm price target lowered to $170 from $200 at Truist
$170.00
(was $123.96)
Richard Newitter
·
Truist Financial
iRhythm price target lowered to $184 from $211 at Goldman Sachs
$184.00
(was $150.96)
Goldman Sachs
iRhythm Technologies (IRTC) PT Lowered to $200 at Truist Securities
$200.00
(was $147.76)
Richard Newitter
·
Truist Financial
iRhythm price target lowered to $200 from $220 at Baird
$200.00
(was $158.88)
Robert W. Baird